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Abstract 
Beyond their role in bone and lung homeostasis, mesenchymal stem cells (MSCs) are becoming popular in cell 
therapy. Various insults may disrupt the repair mechanisms involving MSCs. One such insult is smoking, which 
is a major risk factor for osteoporosis and respiratory diseases. Upon cigarette smoke-induced damage, a series 
of reparatory mechanisms ensue; one such mechanism involves Glycosaminoglycans (GAG). One of these 
GAGs, namely hyaluronic acid (HA), serves as a potential therapeutic target in lung injury. However, much of 
its mechanisms of action through its major receptor CD44 remains unexplored. Our previous studies have 
identified and functionally validated that both cortactin (CTTN: marker of motility) and Survivin (BIRC5: 
required for cell survival) act as novel HA/CD44-downstream transcriptional targets underpinning cell motility. 
Here, human MSCs were treated with “Water-pipe” smoke to investigate the effects of cigarette smoke 
condensate (CSC) on these HA-CD44 novel signaling pathways. Our results show that CSC decreased the 
expression of both CD44 and its downstream targets CTTN and BIRC5 in MSCs, and that HA reversed these 
effects. Interestingly, CSC inhibited migration and invasion of MSCs upon CD44-targeted RNAi treatment. This 
shows the importance of CD44-HA/CTTN and CD44-HA/BIRC5 signaling pathways in MSC motility, and 
further suggests that these signaling pathways may provide a novel mechanism implicated in migration of MSCs 
during repair of lung tissue injury. These findings suggest that one should use caution before utilizing MSC from 
donors with history of smoking, and further pave the way towards the development of targeted therapeutic 
approaches against CD44-associated diseases. 
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Introduction 
Cigarette smoking is a common risk factor for 
numerous systemic conditions, including respiratory 
diseases and osteoporosis.  Cigarette smoke can cause 
DNA damage, free radical production, inflammation 
and lung cell injury, all of which negatively affect 
homeostasis of the lung [1-4]. Furthermore, it disrupts 
various cellular mechanisms implicated in the repair 
of the damage [1-4]. 
Bone marrow mesenchymal stromal cells (MSCs) 
participate in the maintenance and repair of bone as 
well as acts as a reservoir of progenitor cells for 
various solid organs. This “reservoir” capacity allows 
it to contribute to the regeneration of mesenchymal 
tissues in the event of injury [1-4]. In the lung, MSCs 
play a pivotal role in the regeneration of almost all cell 
types, thereby boosting repair mechanisms [1-4]. 
Beyond their role in bone homeostasis, ex vivo 
expanded MSCs have also attracted considerable 
attention for their potential in cell therapy of a wide 
variety of pathological conditions [2-7]. However, this 
potential of MSCs is detrimentally affected by 
cigarette thus reducing their therapeutic potency [8,9].   
Glycosaminoglycans (GAGs) can protect against 
cigarette smoke-induced damage by potentiating 
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repair process of smoke-mediated DNA damage. 
Indeed, when normal proteoglycan synthesis is 
disrupted using specific proteoglycan inhibitors, 
emphysematous changes and parenchymal 
destruction were observed [1-4]. Furthermore, 
senescence and emphysema have been associated 
with a decrease in the GAG species of the lung [1-4].  
In particular, hyaluronan or HA has been reported to 
play a critical role in the repair process of lung tissue 
in emphysema. Reduction in HA content is also 
correlated with increased degradation of elastin by 
elastases [1-4].  This is likely due to the fact that HA, 
along with other GAGs, can form a protective barrier 
that prevents access of elastases to elastin [1-4].  In 
animal studies, intratracheal or aerosolic HA 
supplementation protected elastin fibers from 
degradation, a role that was compromised by 
hyaluronidase and lysozyme [1-4]. 
Binding HA to CD44 is involved in a multitude 
of functions, including cell adhesion, motility, 
angiogenesis and inflammation [10,11]. Indeed, CD44 
is one of the most abundant receptors on MSC and 
plays a major role in cell migration in response to 
chemotactic stimuli. The signaling pathways involved 
during HA-CD44 interaction have been mostly 
investigated in cancer [12]. Several studies have 
established a positive correlation between cell 
invasiveness and increased expression of HA, HAS2 
(HA synthase 2), HYAL2 (hyaluronidase 2), and CD44 
[13,14]. However, the molecular pathways implicated 
in HA-CD44-induced migration of MSCs stimulated 
by nicotine, a key component of cigarette-smoke, are 
nascent. 
We have previously identified and validated 
Cortactin (CTTN) [15], Survivin (BIRC5) [16], and 
TGF-β [17] as novel downstream transcriptional target 
genes in the HA/CD44 signaling pathway.  Nicotine 
decreased CD44 in rodent bone marrow stromal cells 
[18]. Here, we examined the role of CD44-HA 
interaction in migration of MSCs exposed to cigarette 
smoke. We provide exciting evidence implicating 
CD44-HA/CTTN and CD44-HA/BIRC5 in MSC cell 
motility. Taken together, our results suggest that these 
signaling pathways may provide a novel target in 
modulating migration of MSCs during repair of lung 
tissue injury. 
Results 
Establishment of the optimal dose of CSC 
affecting CD44   
Prior to examining the effect of CSC in MSCs, 
AlamarBlue® proliferation assay was utilized to 
determine the optimal dose of CSC required for all the 
experiments (Figure 1). MSC cells were seeded at 
2x104 cells on Costar black tissue culture plates and 
were allowed to attach overnight. The cells were 
treated with medium containing various doses of 
CSC. AlamarBlue® was added to all the wells. Cells 
were observed at appropriated time points for 
morphological changes and fluorometric readings 
were taken at excitation of 540nm and emission 
610nm.  
 
 
Figure 1. Time- and dose-dependent effect of CSC on the proliferation of MSC. Time and dose-dependent effect of CSC on the proliferation of MSCs. Based on the 
growth curves obtained, 6% CSC (~80 %) was selected as an optimal dose for further experiments. 
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Figure 2. CSC decreases both CD44 RNA and protein Expression levels in 
MSC.  (A) CSC decreases CD44 RNA expression levels in MSC. (B) CSC decreases 
CD44 protein expression levels in MSC. Hyaluronic Acid ameliorates CSC effect on 
CD44 Expression in MSC.  
 
The results showed a time and dose-dependent 
effect of CSC on the proliferation of MSCs. 
Interestingly cell proliferation decreased in due 
course of time rather than an abrupt change indicating 
an induction of cell death by specific mechanism 
rather than a toxic effect of CSC. Based on the growth 
curves obtained, 6% CSC (~80 %) was selected as an 
optimal dose to evaluate the actions of CSC on MSCs. 
CSC decreases both CD44 RNA and protein 
Expression levels in MSC 
Hylorunan (100μg/ml), a known ligand of CD44 
showed high expression of CD44 expression was used 
as a control (Figures 2A and B). The RT-PCR results 
showed a marked decrease in the expression of CD44 
mRNA with increasing concentrations of CSC in the 
media (Figure 2 A). Similarly, the effect of CSC on 
CD44 protein expression was performed by western 
blot analysis showing a decrease of CD44 protein.  
HA ameliorates the CSC effect on CD44 
expression in MSC 
After establishing the effect of CSC in decreasing 
the expression levels of CD44 both at RNA and 
protein levels, we tested the hypothesis whether HA 
could reverse this effect (Figure 3). When MSCs were 
treated with increasing concentrations of CSC, 
dose-dependent decrease in CD44 protein expression 
was observed (Fig. 3A). Interestingly however, 
treatment with HA completely abolished CSC’s effect 
on CD44 protein expression (Fig. 3A). These results 
were further confirmed by immunocytochemistry, 
showing similar expression patterns of CD44 in both 
control and CSC-treated MSCs in the absence or 
presence of HA (Fig. 3B). 
 
 
Figure 3. Hyaluronan (HA) ameliorates the CSC effect on CD44 expression in MSC. (A) While CSC decreased CD44 protein expression, treatment with HA 
reversed CSC’s effect on CD44 protein expression. Shown are the cropped blot images representing indicated proteins, and all the gels from three separate experiments have 
been run under the same experimental conditions. (C) Immunocytochemical images showing hyaluronic acid ameliorating CSC effect on CD44 Expression in MSC. 
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Figure 4. CSC inhibits both Cortactin and Survivin RNA expression levels 
parallel to CD44 expression. (A) CSC-reduced CD44 RNA levels paralleled 
CTTN RNA expression levels. (B) CSC-reduced CD44 RNA levels paralleled BIRC5 
RNA levels. Shown are the cropped blot images representing indicated proteins, 
and all the gels from three separate experiments have been run under the same 
experimental conditions. 
 
CSC inhibits both Cortactin and Survivin 
Expression levels parallel to CD44 
We have recently discovered that CD44 can 
impair cancer cell migration and invasion via its two 
novel transcriptional downstream targets, CTTN [15], 
Survivin (BIRC5) [16]. To test whether CSC-decreased 
CD44 expression also decreases its transcriptional 
targets, CTTN and BIRC5, we examined their 
respective RNA (Figure 4) and protein (Figure 5) 
expression levels, using RT-PCR and western blot 
analyses, respectively.  
 
 
Figure 5. CSC inhibits both Cortactin and Survivin protein expression 
levels parallel to CD44 protein expression. (A) CSC-reduced CD44 protein 
expression levels paralleled CTTN protein expression levels. (B) CSC-reduced 
CD44 protein expression levels paralleled BIRC5 protein expression levels. Shown 
are the cropped blot images representing indicated proteins, and all the gels from 
three separate experiments have been run under the same experimental conditions. 
 
In fact, when CD44 expression levels were 
reduced both at RNA and protein levels in response to 
CSC treatment of MSCs, both CTTN and BIRC5 
expression levels were reduced (Figures 4 and 5). 
More interestingly, inhibition of CD44 using specific 
CD44 siRNA primers showed the same patterns of 
inhibition of both CD44 transcriptional targets, CTTN 
and BIRC5 (Figures 4 and 5). Taking together, 
CSC-inhibited CD44 expression appears to directly 
affect its CTTN and BIRC5 downstream target 
signaling pathways in response to CSC treatment of 
MSCs. 
CSC impairs migration and invasion 
properties of MSC, mediated through CD44 
signaling  
To test whether CSC treatment of MSCs affecting 
CD44 signaling also affects its associated function in 
MSC migration and invasion, we initially optimized 
CD44 inhibition, using different doses of siRNA as 
shown in Figure 6A. The decrease of CD44 expression 
was dose-dependent of siRNA concentration.  
Similarly to the experiments performed above, 
MSC Cells were treated with CSC (6%) and (10%) 
doses and with media containing siRNA specific to 
CD44. The Boyden chamber assay was carried out to 
measure both migration (absence of Matrigel) as well 
as MSC invasion (presence of Matrigel). In all cases, 
the results showed a marked decrease in migrated 
(Fig. 6B) and invaded (Fig. 6C). These results put 
together suggest that mobilization of MSC cells to 
damaged lung might be mediated by CD44 signaling 
pathways. 
Discussion 
In this study, we examined the effect of cigarette 
smoke on CD44-mediated MSC migration and 
invasion.  Our results showed a marked decrease in 
migrating cells after CSC exposure; this is consistent 
with a previous study demonstrating that CSC 
attenuated fibronectin and platelet-derived growth 
factor stimulated chemotaxis, accompanied by a 
detrimental effect on the regenerative capacity of 
MSCs [19]. 
Cigarette smoke may lead to cell death, inhibit 
MSC growth, and reduce their ability to migrate and 
engraft while increasing their senescence [19]. It has 
also been reported that smoke interferes with the 
function and the normal processes in lung fibroblasts 
and bone marrow stromal cells [20,21]. Our results 
showed a consistent temporal and quantitative 
relationship between CSC and MSC, especially at 
lower concentrations. Concentration-dependent 
decrease in proliferation of MSCs was observed over a 
period of 36 hours, suggesting that growth inhibition 
is unlikely induced by direct toxic effect. Interestingly, 
low doses of CSC stimulated proliferation, while 
higher concentrations decreased MSC proliferation.  
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Figure 6. CSC impairs migration and invasion ability of MSC mediated through CD44. (A) Gradual suppression of CD44 expression using CD44 SiRNA. CD44 
inhibition was optimized by different doses of siRNA. Shown are the cropped blot images representing indicated proteins, and all the gels from three separate experiments 
have been run under the same experimental conditions. (B) Representative images of Boyden chamber membranes represent the number of captured cells during migration, 
illustrating the difference in migrated cell numbers. (C) Graphical representation of invading cells was demonstrated by invasion assay. Note a marked decrease in MSC cell 
migration and invasion capabilities after inhibiting CD44 expression using siRNA. Control cells were cultured in the same conditions. Representative images of Boyden chamber 
membranes represent the number of captured cells during the invasion, illustrating the difference in invaded cell numbers. The difference is considered statistically significant 
(student’s t-test *P<0.001). 
 
CD44 is a transmembrane glycoprotein 
abundantly expressed on the surface of MSCs, and 
commonly used as a characteristic marker for MSC. 
CD44 is essential in the hematopoiesis process, tumor 
metastasis, lymphocyte activation, and MSC homing 
[10,11,22]. It also serves as a link between cells and the 
extracellular matrix, regulating cell adhesion and 
migration [10,11,22]. While HA is its major ligand, 
CD44 can also be activated by other ligands such as 
osteopontin, collagens and fibronectin [11,23-27].  
Nicotine is one element of cigarette smoke that 
inhibits CD44 expression in a group of bone marrow 
stromal cells and in bone marrow derived–endothelial 
cell line (STR-12) [18,28,29]. In our study, we found 
that in response to CSC, a concentration-dependent 
decrease in CD44 expression was observed at both 
mRNA and protein levels. Paradoxically, several 
studies have reported an increase in soluble CD44 in 
smokers, thus suggesting increased production 
and/or increased shedding [30-32]. However, our 
data suggests a transcriptional level inhibitory effect, 
which is not consistent with shedding as the 
mechanism for reduced CD44 expression in our 
experimental setting. 
 There is a significant evidence supporting the 
role of CD44 in migration and homing of MSC; Zhu et 
al., 2006 have demonstrated that CD44 facilitated 
MSC adhesion and migration in murine CD44-/- bone 
marrow stromal cells [33]. Sackstein et al., 
demonstrated that induction of an alternative CD44 
glyco-form on MSCs facilitated their homing [34], 
suggesting the involvement of CD44 in MSC motility. 
Our results support this finding, as RNAi inhibition of 
CD44 clearly suppressed migration and invasion of 
MSC.  
HA is the major ligand for CD44 In emphysema, 
HA forms a complex with other GAGs to provide a 
protective shield that blocks access of CSC to 
molecules such as elastin, [35]. HA also targets CD44 
and inhibits FcepsilonR1 signaling that involves ROS 
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and MAPK [18,36]. Our results showed that 
CSC-induced reduction in CD44 expression was 
abolished when cells were treated with HA (Fig. 2). 
This confirms the protective effect that HA imparts 
against CSC-induced cell damage. Interestingly, 
smoking increases mucin production and mucus 
hypersecretion in a ROS-dependent manner [34]. This 
aggravated mucus secretion in airway epithelia 
appears to be directly related to depolymerization of 
hyalouronan [34]. Depolymerization of HA is 
pathologically an important process, since functions 
of HA are size-dependent, and low-molecular-weight 
HA is considered a “danger signal” [34]. 
We have previously demonstrated using 
Microarray analysis that CD44 promotes breast cancer 
cell invasions and metastasis to the liver [37], and 
identified CTTN [15] and BIRC5 [37] as downstream 
target genes underpinning CD44-promoted cell 
survival, migration and invasion. While CTTN is a 
marker of motility, due to its close relation to the actin 
cytoskeleton, BIRC5 is an elusive protein required for 
the survival of the cells, and these two proteins play a 
key role in lung injury [16,38]. The results of the 
present study revealed that CSC inhibited the 
expression of CD44, which in turn downregulated the 
expression of both its downstream transcriptional 
targets, CTTN and BIRC5. This parallel decrease of 
CTTN and BIRC5 was confirmed by RT-PCR, and 
further confirmed by RNAi inhibition of CD44 
leading to significant reduction in CTTN and BIRC5 
expression. Evidence supports a role of CD44 for 
homing of hematopoietic precursor cells and 
T-lymphocytes [39].  A previous study by Sackstein et. 
al., 2008,  demonstrated induction of an alternative 
CD44 glycoform on MSC, which facilitated their 
homing to the bone, suggesting the importance of 
CD44 in MSC motility [34]. Our results support this 
finding, as inhibition of CD44 with specific iRNA 
strongly suppressed migration and invasion of MSC 
cells (Fig. 4). Inhibition of CD44 with RNAi strongly 
suppressed migration and invasion of the MSC cells. 
This indicates the importance of CD44-downstream 
signaling in MSC  motility [34]. These data providing 
a clear evidence that CD44 signaling are vital for 
migration and invasion of MSC are supported by 
recent studies, emphasizing the regenerative potential 
of MSCs in the development of future cell-based 
clinical trials and therapies. 
In summary, this study demonstrates the 
potential involvement of CD44 in the impairment of 
MSC migration and invasion in cigarette smokers (or 
in response to cigarette smoke). Furthermore, our 
findings suggest that this mechanism is mediated 
through a dual transcriptional regulation of CTTN 
and BIRC5 by CD44. These findings provide insights 
into potential novel mechanisms by which smoking 
may contribute to the development of osteoporosis, 
lung injury and emphysema, and further suggest that 
a caution must be taken before using smokers’ MSC as 
source for cell therapy.  In addition to a better 
understanding of the mechanisms by which CD44 
mediates cigarette smoke-suppressed MSC cell 
motility, this investigation identified CD44/CTTN 
and CD44/BIRC5 signaling pathways as potential 
targets to pave the way towards the design of 
therapeutic strategies against cancer, emphysema and 
other CD44-associated diseases [40]. 
Materials and Methods 
Cell Culture 
Human bone marrow derived human MSC 
(MSC) were obtained from the Tulane Center of Gene 
Therapy (New Orleans, LA) and cultured in α-MEM 
medium containing 16.5% FBS (v/v, Atlanta 
Biologicals, Miami, FL), 2 mM L-Glutamine at 37°C 
with 5% carbon dioxide. The media was 
supplemented with dried sodium hyaluranon 
(Lifecore Biomedical, MN, U.S.A) at 100µg/ml 
concentration. All experiments were conducted with 
cells cultured to 60% confluence. Cigarette smoke 
condensate (CSC) was prepared by bubbling 40 ml of 
plain α-MEM with four 3R4F Reference Research 
Cigarettes (The University of Kentucky, College of 
Agriculture, Lexington, KY) at a negative pressure of 
10 cm H2O, pH adjusted to 7.4 and filtered with 0.22 
µm. This was used as 100% and diluted as desired in 
further experiments.  The CSC was prepared fresh for 
each experiment and added to fresh media to achieve 
the desired concentration (final concentration of 5% 
FBS for all conditions). Control media was prepared 
in a similar fashion except room air was bubbled 
through the media. 
Antibodies, Chemicals & reagents 
The following antibodies were used: Mouse 
polyclonal anti-CD44 (R&D systems), mouse 
monoclonal anti-CD44 (Santa Cruz Biotechnology, 
CA), rabbit polyclonal anti-GAPDH (Santa Cruz 
Biotechnology, CA), mouse monoclonal anti CTTN 
(Upstate cell signaling solution), rabbit monoclonal 
anti BIRC5 (Santa Cruz Biotechnology), goat 
anti-mouse IgG HRP CD44 (Santa Cruz 
Biotechnology), goat anti-rabbit IgG HRP CD44 (Santa 
Cruz Biotechnology) antibodies. 
Proliferation Assay 
The AlamarBlue® cell proliferation assay 
(Invitrogen, Carlsbad, CA) was utilized to determine 
the toxicity of CSC on MSC.  MSC were seeded at 
2x104 cells on Costar black tissue culture plates and 
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allowed to attach overnight. The cells were then 
incubated in media containing various doses of CSC 
and AlamarBlue® was added to all the wells. Cells 
were observed at serial time points for morphological 
changes and fluorometric readings were taken at 
excitation of 540 nm and emission 610 nm.  
Cell Migration and Invasion Assays 
Migration and invasion chambers were prepared 
by coating cell culture inserts (12 µm pore size, 
Millipore, MA) with 200 µg/ml of Matrigel™ (BD 
Biosciences, MA), which serves as a basement 
membrane substitute corresponding to the basement 
membrane of blood vessels. Assays were conducted 
using MSC exposed to CSE, control media as well as 
with media containing RNAi of CD44 for four hours 
as previously described [40]. After trypsinization cells 
were resuspended in α-MEM with 1% FBS at 5 x105 
cells/200µl/well, added to the upper chamber and 
then incubated for 24-hrs at 37°C. After 4 hours, the 
cells were detached and seeded into transwell 
membranes (pore size-12µm) with serum deficient 
media placed in 12 well plates containing 1% FBS 
containing MEM –alpha medium. The 12 well plates 
were incubated for 24 hours at 5% CO2 and 37°C. At 
the end of 24 hours, the upper surface of the filter was 
then wiped with a cotton swab to remove 
non-migratory cells. The cells attached to the other 
side of filter were stained with a Diff-Quick stain set 
(Dade Behring Inc.), photographed under a 
phase-contrast microscope and the total number of 
stained cells for each filter was tabulated using a 
counting grid.  
Western blotting 
Cell lysates were prepared from cells treated for 
24 hours with bubbled CSC or control media and the 
final protein concentration in the supernatant was 
determined using the Bradford Protein Assay Reagent 
(Sigma-Aldrich, St. Louis, MO) as previously 
described [40]. Samples (60µg) were boiled for 5 
minutes in an equal volume of reducing buffer and 
resolved on 12% polyacrylamide gels and 
electroblotted onto PVDF membranes. Membranes 
were probed with mouse anti-CD44 (1:2000 dilution, 
R& D systems), mouse monoclonal anti CTTN 
antibody (1:2000 dilution, Upstate cell signaling 
solution), rabbit monoclonal anti BIRC5 antibody 
(1:2000 dilution, Santa Cruz Biotechnology)and goat 
anti-GAPDH antibody (1:2000 dilution, Santa Cruz, 
CA) and detected with a goat anti-mouse and donkey 
anti-goat IgG-HRP (1:5000 dilution, Santa Cruz, CA) 
using chemiluminescence (Supersignal West Femto, 
Pierce).  
Preparation of RNA samples  
Cells were treated with CSC and harvested after 
12 and 24 hours. RNA was isolated using RNeasy 
Mini kit (Qiagen) according to the manufacturer’s 
recommendations. Isolated RNA samples were 
assessed for quantity and purity (NanoDrop 
Technologies Inc. DE, USA) and stored at -80 0C for 
further analysis. 
RT-PCR Analysis 
For RT-PCR analysis (Qiagen One Step RT-PCR 
kit), 1.0 µg of total RNA was reverse transcribed using 
standard reagents according to the manufacturer’s 
instructions. Samples were incubated in the PTC-200 
Thermal Cycler for reverse transcription at 50°C for 30 
min, initial PCR activation step at 95°C for 5 min 
followed by 32 polymerase chain reaction cycles. Each 
cycle consisted of at 95˚C for 30 seconds, 56˚C for 30 
seconds, and 68˚C for 1 minute. The final completion 
step was carried out at 68˚C for 10 minutes. The 
annealing temperatures for various genes were 
calculated according to their sequence and were 
optimized. Accordingly, the temperatures we used 
were: 55˚C for CD44 and CTTN, 51˚C for BIRC5 and 
58˚C for GAPDH.  
The following oligonucleotide primers were 
used: CD44: TTTGCATTGCAGTCAACAGTC (sense) 
and TTACACCCCAATCTTCATGTCCAC (anti-
sense); CTTN: AAAGCTTCAGCAGGCCAC (sense) 
and TTTGGTCCTGTTTCAAGTTCC (antisense); 
BIRC5: AGCCCTTTCTCAAGGACCA (sense) and TC 
AATCCATGGCAGCCAG (antisense); GAPDH: ACC 
ACAGTCCATGCCATCAC (sense) and TCCACCAC 
CCTGTTGCTGTA (antisense).  The RT-PCR products 
were examined by electrophoresis in 2% agarose gel 
containing 0.2 μg/ml ethidium bromide. 
RNAi-Mediated Depletion of CD44  
Specific human CD44 siRNA oligonucleotides 
(5'-GGAAAUGGUGCAUUUGGUGtt-3' and 3'-CAC 
CAAAUGCACCAUUUCCtt-5') and a Silencer® 
Negative Control #1 siRNA were synthesized 
commercially (Ambion, TX). Cells were seeded and 
grown to 50% confluency, washed twice in sterile PBS, 
then incubated with a transfection cocktail comprised 
of OPTI-MEM, Lipofectamine-2000 (Invitrogen) and 
the siRNA or scrambled oligonucleotides, at final 
concentrations of 100 and 200 nM for 24 hours at 37°C. 
Next day, cells were treated once more with the 
siRNA cocktail. Transfected cells were incubated at 
37°C for an additional 24 hours before harvest and 
were then used in experiments. Depletion of CD44 
expression in cells was confirmed by immunoblotting.  
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Statistical Analysis  
Differences between mean and standard 
deviation were assessed for statistical significance 
using one-way ANOVA with Newman-Keuls 
Multiple Comparison Test (GraphPad InStat version 
5.00, GraphPad Software, CA). p value less than 0.05 
was considered significant. 
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